Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis

By afschroeder • August 17, 2025

Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos L, Molteni E, Lipsyc-Sharf M, Gianni C, Bayou N, Dai CS, Giannarelli D, Bria E, Ma CX, Bardia A, Reduzzi C, Cristofanilli M. Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis. NPJ Breast Cancer. 2025 Aug 16;11(1):93. doi: 10.1038/s41523-025-00802-2. PMID: 40819062; PMCID: PMC12357851.

Tags: Hematology/Oncology, Publications

Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer

Chan AA, Sankar K, Reckamp KL, Díaz B, Lee DJ. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung[...]

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]

Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients

Eckardt MA, Siena NM, Copeland AR, McCaw TR, Shehata MS, Lofftus SY, Graham DS, Dao HB, Singh AS, Chmielowski B, Federman N, Kadera BE, Kalbasi[...]